Cerus Appoints Carol M. Moore as Vice President, Regulatory Affairs and Quality

Cerus Corporation (NASDAQ: CERS) announced today that Carol M. Moore has been appointed vice president, regulatory affairs and quality. In that position, Ms. Moore will be responsible for implementing global strategies for registration and regulatory compliance and with maintaining ISO quality standards related to the INTERCEPT Blood System.

Prior to joining Cerus, Ms. Moore was vice president, worldwide regulatory affairs for Bayer Corporation. In that position, she held primary responsibility for interactions with health authorities worldwide involving the registration and regulatory compliance of Bayers biological and biotech products. She was involved at Bayer in health policy, strategic planning, product development and acquisition assessment for a growing product portfolio. From 1999 to 2001, Ms. Moore was Bayers vice president, quality assurance and regulatory affairs. She began her career at Bayer in 1976. Bayers biological products include those derived from recombinant and monoclonal sources, as well as transgenic and plasma-derived.

Cerus is very pleased to welcome Carol Moore to our senior management team, said Claes Glassell, president and CEO of Cerus Corporation. Her global experience, particularly in plasma-derived products, is directly applicable to the commercialization of the INTERCEPT Blood System in markets around the world. I look forward to her contributions not only directly in the regulatory and quality areas, but also strategically in clinical and product development.


Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Cerus Corporation
William J. Dawson, Vice President, Finance & CFO
Porter Novelli Life Sciences
Jason I. Spark, Account Director

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.